In vivo validation of DNA adduct formation by estragole in rats predicted by physiologically based biodynamic modelling.

Estragole is a naturally occurring food-borne genotoxic compound found in a variety of food sources, including spices and herbs. This results in human exposure to estragole via the regular diet. The objective of this study was to quantify the dose-dependent estragole-DNA adduct formation in rat liver and the urinary excretion of 1'-hydroxyestragole glucuronide in order to validate our recently developed physiologically based biodynamic (PBBD) model. Groups of male outbred Sprague Dawley rats (n = 10, per group) were administered estragole once by oral gavage at dose levels of 0 (vehicle control), 5, 30, 75, 150, and 300mg estragole/kg bw and sacrificed after 48h. Liver, kidney and lungs were analysed for DNA adducts by LC-MS/MS. Results obtained revealed a dose-dependent increase in DNA adduct formation in the liver. In lungs and kidneys DNA adducts were detected at lower levels than in the liver confirming the occurrence of DNA adducts preferably in the target organ, the liver. The results obtained showed that the PBBD model predictions for both urinary excretion of 1'-hydroxyestragole glucuronide and the guanosine adduct formation in the liver were comparable within less than an order of magnitude to the values actually observed in vivo. The PBBD model was refined using liver zonation to investigate whether its predictive potential could be further improved. The results obtained provide the first data set available on estragole-DNA adduct formation in rats and confirm their occurrence in metabolically active tissues, i.e. liver, lung and kidney, while the significantly higher levels found in liver are in accordance with the liver as the target organ for carcinogenicity. This opens the way towards future modelling of dose-dependent estragole liver DNA adduct formation in human.

[1]  P. van Bladeren,et al.  Identification of nevadensin as an important herb-based constituent inhibiting estragole bioactivation and physiology-based biokinetic modeling of its possible in vivo effect. , 2010, Toxicology and applied pharmacology.

[2]  L. Iyer,et al.  Glucuronidation of 1'-hydroxyestragole (1'-HE) by human UDP-glucuronosyltransferases UGT2B7 and UGT1A9. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[3]  E C Miller,et al.  Structure-activity studies of the carcinogenicities in the mouse and rat of some naturally occurring and synthetic alkenylbenzene derivatives related to safrole and estragole. , 1983, Cancer research.

[4]  R. de Kanter,et al.  Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction , 2006, Expert opinion on drug metabolism & toxicology.

[5]  K. Lindros.  Zonation of cytochrome P450 expression, drug metabolism and toxicity in liver. , 1997, General pharmacology.

[6]  J. Caldwell,et al.  Metabolism of estragole in rat and mouse and influence of dose size on excretion of the proximate carcinogen 1'-hydroxyestragole. , 1987, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[7]  Ans Punt,et al.  Tutorial on physiologically based kinetic modeling in molecular nutrition and food research. , 2011, Molecular nutrition & food research.

[8]  P. Rudnai,et al.  Correlation between biomarkers of human exposure to genotoxins with focus on carcinogen-DNA adducts. , 2007, Mutagenesis.

[9]  B. Wong,et al.  Complexities of glucuronidation affecting in vitro in vivo extrapolation. , 2002, Current drug metabolism.

[10]  E C Miller,et al.  Structures of the DNA adducts formed in mouse liver after administration of the proximate hepatocarcinogen 1'-hydroxyestragole. , 1981, Cancer research.

[11]  S. Kyrtopoulos,et al.  Detection and quantitation of benzo[a]pyrene-derived DNA adducts in mouse liver by liquid chromatography-tandem mass spectrometry: comparison with 32P-postlabeling. , 2006, Chemical research in toxicology.

[12]  Gary M Williams,et al.  DNA-Reactive Carcinogens: Mode of Action and Human Cancer Hazard , 2005, Critical reviews in toxicology.

[13]  P. Novikoff,et al.  Distribution of UDPglucuronosyltransferase in rat tissue. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Rychlik,et al.  Study of the metabolism of estragole in humans consuming fennel tea. , 2009, Chemical research in toxicology.

[15]  P. van Bladeren,et al.  Human cytochrome p450 enzyme specificity for the bioactivation of estragole and related alkenylbenzenes. , 2007, Chemical research in toxicology.

[16]  Benoît Schilter,et al.  Tandem mass spectrometry analysis of N2-(trans-Isoestragol-3'-yl)-2'-deoxyguanosine as a strategy to study species differences in sulfotransferase conversion of the proximate carcinogen 1'-hydroxyestragole. , 2007, Chemical research in toxicology.

[17]  K Randerath,et al.  32P-post-labelling analysis of DNA adducts formed in the livers of animals treated with safrole, estragole and other naturally-occurring alkenylbenzenes. II. Newborn male B6C3F1 mice. , 1984, Carcinogenesis.

[18]  Benoît Schilter,et al.  A physiologically based biokinetic (PBBK) model for estragole bioactivation and detoxification in rat. , 2008, Toxicology and applied pharmacology.

[19]  Ans Punt,et al.  Differences in simulated liver concentrations of toxic coumarin metabolites in rats and different human populations evaluated through physiologically based biokinetic (PBBK) modeling. , 2008, Toxicology in vitro : an international journal published in association with BIBRA.

[20]  H. Tran,et al.  A Multicompartment Liver-based Pharmacokinetic Model for Benzene and its Metabolites in Mice , 2010, Bulletin of mathematical biology.

[21]  K. Lindros,et al.  Zonation of hepatic cytochrome P-450 expression and regulation. , 1998, The Biochemical journal.

[22]  Stephen J. Fallows,et al.  Scientific Committee on Food , 2000 .

[23]  K. Bock,et al.  Intralobular distribution of UDP-glucuronosyltransferase in livers from untreated, 3-methylcholanthrene- and phenobarbital-treated rats. , 1984, Chemico-biological interactions.

[24]  A. Nishikawa,et al.  Detection and quantification of specific DNA adducts by liquid chromatography-tandem mass spectrometry in the livers of rats given estragole at the carcinogenic dose. , 2011, Chemical research in toxicology.

[25]  A. Mally,et al.  Absence of 2'-deoxyguanosine-carbon 8-bound ochratoxin A adduct in rat kidney DNA monitored by isotope dilution LC-MS/MS. , 2008, Molecular nutrition & food research.

[26]  Alicia Paini,et al.  A physiologically based biodynamic (PBBD) model for estragole DNA binding in rat liver based on in vitro kinetic data and estragole DNA adduct formation in primary hepatocytes. , 2010, Toxicology and applied pharmacology.

[27]  J. Caldwell,et al.  Immunochemical detection of covalently modified protein adducts in livers of rats treated with methyleugenol. , 1996, Chemical research in toxicology.

[28]  J I Goodman,et al.  Safety assessment of allylalkoxybenzene derivatives used as flavouring substances - methyl eugenol and estragole. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[29]  S. Wrighton,et al.  In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[30]  Andreas P. Freidig,et al.  Use of Physiologically Based Biokinetic (PBBK) Modeling to Study Estragole Bioactivation and Detoxification in Humans as Compared with Male Rats , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[31]  Gary M Williams,et al.  Application of mode-of-action considerations in human cancer risk assessment. , 2008, Toxicology letters.

[32]  H. Marquardt,et al.  32P-post-labelling analysis of DNA adducts formed by food-derived heterocyclic amines: evidence for incomplete hydrolysis and a procedure for adduct pattern simplification. , 1994, Carcinogenesis.